Breaking News, Collaborations & Alliances

Invenra & Catalent Team Up to Develop Next-Gen Cancer Therapies

Aim to harness the combined expertise and proprietary technologies of both companies to co-discover novel bispecific antibody-drug conjugates.

Author Image

By: Charlie Sternberg

Associate Editor

Invenra Inc., a leader in bispecific antibody technology, has entered a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in drug development solutions, which aims to harness the combined expertise and proprietary technologies of Invenra and Catalent to co-discover novel bispecific antibody-drug conjugates.   Dr. Roland Green, CEO of Invenra, remarks, “We are excited to collaborate with the innovative team at Catalent’s Redw...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters